Merck Hits Brakes On Anti-PD-1/TIGIT Study In Adjuvant Melanoma

Industry-wide, the combination of PD-1/PD-L1 inhibitors with TIGIT inhibitors has produced a mixed bag in terms of results.

• Source: Shutterstock

Merck & Co., Inc. is closing down the Keytruda (pembrolizumab) and vibostolimab coformulation arm of a Phase III melanoma trial after an analysis showed a higher dropout rate compared with the Keytruda-only arm due to adverse events, chalking up another loss for anti-PD-1/TIGIT combinations.

The Rahway, NJ-based drug maker said 13 May that a preplanned analysis of the KeyVibe-010 trial comparing the coformulation against...

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.